Sanofi Makes $30 Million Strategic Investment in GluBio Therapeutics to Advance Molecular Glue Degraders for Sickle Cell Disease
February 11, 2026Sanofi to make a $30 million strategic equity investment in GluBio Therapeutics.
Sanofi to receive a right of first negotiation, or ROFN, for a potential future exclusive license to GLB-005 and GLB-007, GluBio’s lead molecular glue degrader programs for sickle cell disease.
San Diego and Shanghai, Feb. 11, 2026 – GluBio Therapeutics (“GluBio”), a clinical-stage biotechnology company dedicated to the discovery and development of innovative molecular glue degraders (MGDs), today announced a $30 million strategic equity investment from Sanofi. The investment will support the advancement of GluBio’s two lead programs, GLB-005 and GLB-007, which are being developed as potential disease-modifying therapies for sickle cell disease (SCD).
Under the terms of the agreement, Sanofi has subscribed to a newly issued series of preferred shares in GluBio. In addition, GluBio has granted Sanofi an exclusive right of first negotiation (ROFN) for a potential exclusive license to research, develop, manufacture, and commercialize GLB-005 and GLB-007. Phase 1 clinical trials are expected to start later this year.
GluBio’s GLB-005 is designed to selectively degrade WIZ, while GLB-007 targets both WIZ and ZBTB7A. By degrading these fetal hemoglobin repressors, GluBio’s candidates aim to activate fetal hemoglobin expression, potentially offering an oral, disease-modifying treatment for patients with sickle cell disease.
"We are delighted to welcome Sanofi, a global leader in rare blood disorders, as a strategic investor," said Dr. Gang Lu, Chief Executive Officer of GluBio Therapeutics. "This investment validates the strength of our molecular glue degrader platform and the potential of our lead programs to deliver meaningful, disease-modifying therapies for patients with sickle cell disease. Sanofi's strategic interest will help accelerate our progress toward the clinic."
About GluBio Therapeutics
GluBio Therapeutics Inc. ("GluBio") is a global biotechnology company focused on the discovery and development of novel molecular glue degraders (MGDs), to address unmet medical needs across genetic disorders, oncology, and autoimmune diseases. As a leader in the field, GluBio leverages its proprietary Glue Degrader Discovery (GDD©) platform to drive systematic innovation. The company has built an integrated R&D engine comprising target identification and validation, multi-dimensional protein degradation screening, AI-driven molecular glue rational design, and a diverse proprietary compound library.
For more information, please visit www.glubiotx.com.